ISSUE: The use of quantitative patient preference information (PPI) in regulatory decision-making is increasing. In contrast, its application in health technology assessment (HTA) is less frequent. The aim of this issue panel is to debate whether there are opportunities for increased use of quantitative PPI in HTA. The panelists will draw upon their experiences in the United Kingdom, the United States and Canada. David Mott will provide an overview of the use of quantitative PPI to inform health care decision-making and put forward a number of reasons as to why HTA appears to be falling behind. Brett Hauber will discuss the recent progress in the regulatory space, explaining how PPI in regulatory decisions has become better defined and how this may differ to the type of information that is required for HTA. Deborah Marshall will consider the challenge for HTA assessment processes in incorporating and weighing PPI with clinical, cost-effectiveness and budget impact information. In the remainder of the session, the audience will be encouraged to put forward their thoughts in an open debate on the subject. OVERVIEW: Quantitative PPI can be generated using a range of stated preference methodologies including, but not limited to: time trade-off; contingent valuation; discrete choice experiments; and best-worst scaling. The data can be used within, or considered alongside, analyses that aim to inform health care decision-making, such as benefit-risk assessments and HTAs. In the United States, the Food and Drug Administration (FDA) has taken major steps forward to encourage the incorporation of the patient perspective into regulatory decision-making. With related research projects currently ongoing, regulatory agencies in Europe may follow the FDA’s lead in the near future. However, despite the potential and the progress being made in the regulatory space, there is currently little to suggest that HTA agencies will encourage greater utilisation of quantitative PPI.